Result card

  • SAF11: How can one increase safety of patients tested with uPA/PAI-1, Oncotype DX, or MammaPrint® (including technology-, user-, and patient-dependent aspects)?
English

How can one increase safety of patients tested with uPA/PAI-1, Oncotype DX, or MammaPrint® (including technology-, user-, and patient-dependent aspects)?

Authors: Iris Pasternack, Emilio Chiarolla, Narine Sahakyan, Leonor Varela

Internal reviewers: Pseudo100 Pseudo100, Pseudo163 Pseudo163, Pseudo169 Pseudo169, Pseudo219 Pseudo219, Pseudo90 Pseudo90, Pseudo94 Pseudo94

A search was done in PubMed by IP on 15 March 2012 using search string

  • 3 Add Search (safety[Title/Abstract]) AND #2 >18 studies
  • 2 Add Search (surgical pathology[Title/Abstract]) AND #1 246
  • 1 Add Search quality[Title/Abstract] 449032

See {Appendix SAF-4}

T = all surgical pathology activities

I = interventions which improve quality and safety

C = NR

O = patient safety

Clinical practitioners play an essential role in error reduction through several avenues such as effective test ordering, providing accurate and pertinent clinical information, procuring high quality specimens, providing timely follow-up on test results, effectively communicating on potentially discrepant diagnoses, and advocating second opinions on the pathology diagnosis in specific situations (1).

An important component of improving patient safety is reducing medical errors. A step towards reducing the errors is their identification. Mislabelling occurred significantly less in study laboratories with continuous individual-case (one by one) accessioning and in laboratories with formal, documented quality checks at accessioning (5). Systematic monitoring and subsequent evaluation of various aspects of hospital and laboratory practices is suggested (See TEC and/or ORG domain for quality assurance).

Important
Partially
Pasternack I et al. Result Card SAF11 In: Pasternack I et al. Safety In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 28 November 2021]. Available from: http://corehta.info/ViewCover.aspx?id=113